Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
•
Stereotactic Body Radiotherapy
•
Prostate Cancer
What fractionation and dose constraints do you use for prostate SBRT?
Answer from: Radiation Oncologist at Community Practice
UCLA King Protocol8 Gy x5PTV 95% of PTV volume to get 95-110% rx doseRectum V50 (20 Gy) < 50%V80 (32 Gy) < 20%V90 (36 Gy) < 10 %V100 (40Gy) < 5%BladderV50 (20 Gy) < 40%V100 (40 Gy) < 1.1%Femurs V40 (16 Gy) < 5%Small Bowel V50 (20Gy) < 1%
Sign in or Register to read more
380
Related Questions
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
Do you offer prostate RT to men with 0-3 bone metastases on conventional imaging when PSMA PET shows a very high number of M1 lesions?
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
How would you plan sequencing of an MRI-directed prostate nodule micro-boost when doing a sequential plan?
Would you ever omit or reduce prostate bed radiation in a post-prostatectomy patient who develops recurrence in pelvic LNs?
Would you offer salvage radiation for a local recurrence of prostate cancer that was initially treated with SBRT?
How do you counsel NCCN low and very low risk prostate cancer patients who receive a high risk DECIPHER score?
When treating prostate cancer with moderate hypo-fractionation, what urethral dose constraints do you consider when boosting the dominate intraprostatic lesion?
What is your preferred dose to gross lymph nodes when treating non-metastatic high-risk prostate cancer?